

Special Issue

Diagnostics, Antiviral Therapy and Vaccination Against Orthopoxvirus Infections (2nd Edition)

Message from the Guest Editor

In the decades since the eradication of smallpox, the human population has almost completely lost herd immunity, not only against smallpox but also against other zoonotic orthopoxviruses. This has led to an increasing number of outbreaks of human infections caused by monkeypox, cowpox, buffalopox, or vaccinia viruses being recorded on different continents, and the risk of widespread epidemics of orthopoxvirus infections is also increasing. Therefore, the development of new diagnostic methods and the creation of antivirals and modern vaccines against orthopoxviruses are of particular importance. This Special Issue will present the latest research findings on the development of express diagnostic methods, the search for effective antivirals, and the creation of safe modern vaccines against orthopoxvirus infections.

Guest Editor

Prof. Dr. Sergei N. Shchelkunov

State Research Center of Virology and Biotechnology Vector,
Novosibirsk Region, 630559 Koltsovo, Russia

Deadline for manuscript submissions

31 October 2026



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/260973

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).